Study on changes of the levels of EGF, BDNF in serum and their relations with cognitive impairment in patients with Parkinson's disease

Xin-guo YE,Tiao LI,Xiang LI,Li YANG,Cheng-yan LI

2016-01-01

Abstract:Objective To study the changes of serum levels of epidermal growth factor(EGF)and brain derived neurotrophic factor(BDNF)in patients with Parkinson's disease(PD), and to explore the association with cognitive function. Method 76 PD patients were enrolled and 40 age- and gender- matched healthy subjects were used as controls. The information including gender, age, illness duration, years of education and Hoehn &Yahr(H-Y)stage were recorded. Cognitive function of all the patients with PD and the controls were measured by using Montreal Cognitive Assessment(MoCA)scale. The serum levels of EGF and BDNF were measured by ELISA. Results Serum levels of EGF and BDNF in PD group were significantly lower than the control group[(745±148) ng·L-1 vs(952±157)ng·L-1,P<0.05 ;(5.1±3.1)g·L-1 vs(6.8±3.9)g·L-1, P <0.05]. Serum levels of EGF and BDNF were no differences between early PD group and middle-late PD group of patients(P >0.05). Serum levels of EGF in PDh mild cognitive impairment(MCI)were obviously lower than PD group without MCI[(713±146) ng·L-1 vs(865±189)ng·L-1,P <0.01]. In PD patients,MoCA scores were positively correlated with years of education(β=0.611, P <0.01)and serum levels of EGF(β=0.513, P <0.01), and were negatively correlated with illness duration(β=-0.373, P <0.05)and H-Y stag(β=-0.264,P <0.05). Conclusion The changes of serum levels of EGF and BDNF may be involved in the pathogenesis of patients with PD. The lower levels of EGF may be associated with MCI in PD patients. Serum 1evels of EGF may be a potential early predictive index in PD patients with cognitive impairment.